Type 1 Diabetes Autonomic and Vascular Function
Part of paid clinical trials in Austin, Texas.
- Sponsor
- University of Texas at Austin
- Study ID
- NCT06786546
- Status
- Enrolling By Invitation
Conditions
- Diabetes, Autoimmune
- Type 1 Diabetes
- Type 1 Diabetes (Juvenile Onset)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Accepted
Study Details
The goal of this clinical trial is to investigate the autonomic and vascular function in men and women with Type 1 diabetes. The main questions it aims to answer are: 1. Patients with type 1 diabetes exhibit attenuated vascular function during steady-state exercise 2. Patients with type 1 diabetes have altered autonomic function at rest and during exercise pressor reflex 3. Patients with type 1 diabetes have attenuated muscle sympathetic activity
Key Dates
- Start date
- Aug 7, 2023
- Status verified
- Sep 2025
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 72 participants (estimated)
Arms
- Arm: Type 1 Diabetes GroupMen and women diagnosed with Type 1 diabetes
- Arm: Healthy Control groupHealthy men and women will be recruited, matched to the Type 1 diabetes group for age, sex and weight
Primary Outcome Measure
Vascular Function [ Time Frame: Blood flow will be measured at baseline for 5 min in supine position. During exercise, blood flow will be measured continuously for the 3 minutes of handgrip exercise. ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Texas at Austin | Austin | Texas | 78712 | - |
Find similar trials in Austin, TX
By condition
By specialty
By research site
Related Studies
- Immune Function and the Progression to T1DRecruiting · University of Florida · Gainesville, Florida
- EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 DiabetesRecruiting · Baylor College of Medicine · Houston, Texas
- Registry for Stage 2 Type 1 DiabetesRecruiting · Sanofi · Los Angeles, California
- CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)PHASE1/PHASE2 · Recruiting · COUR Pharmaceutical Development Company, Inc. · Tucson, Arizona